Have an account? Log in.
I don't have an account.
Viridian shares fall after Amgen TEPEZZA Phase 3 data shows stronger efficacy, raising concerns over elegrobart's position in the TED market.
Oppenheimer analyst Leland Gershell maintains argenx (NASDAQ:ARGX) with a Outperform and lowers the price target from $1060 to $1014.
Viridian (VRDN) shares plunge 38% premarket despite positive Phase 3 TED trial data. Analysts weigh in on elegrobart's market viability.
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.